In the present study, we investigated the feasibility of generating third-generation CAR-NK-92 cells targeting CD19 and CD138 as well as dual CAR-NK-92 cells cotargeting CD19 and CD138 and evaluated their selective cytotoxicity in vitro toward various hematologic cancer cells with different CD19 and CD138 expression profiles. The gene discussed is CD19; the disease is hematopoietic and lymphoid cell neoplasm.